General Information:

Id: 1,989 (click here to show other Interactions for entry)
Diseases: Cardiovascular disease
Diabetes mellitus, type II - [OMIM]
Insulin resistance
Myocardial infarction - [OMIM]
Nephropathy, diabetic
Neuropathy, diabetic
Retinopathy, diabetic
Stroke, ischemic - [OMIM]
Mammalia
review
Reference: Lardizabal JA and Deedwania PC(2010) The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus Curr Cardiol Rep 12: 464-471 [PMID: 20809236]

Interaction Information:

Comment Bradykinin has been shown to increase insulin sensitivity and enhance skeletal muscle glucose uptake by activating B2 kinin receptors in the muscle cells and by upregulating the GLUT glucose transport system. Bradykinin-potentiated glucose uptake has been demonstrated in cardiac tissue as well.
Formal Description
Interaction-ID: 15666

gene/protein

Bradykinin

increases_activity of

process

glucose import

in skeletal muscle, in cardiac muscle
Comment NO is purported to mediate insulin-related glucose uptake through the same mechanisms as bradykinin. In addition, NO also appears to be the primary mediator for the non–insulin-dependent transport and utilization of glucose in the skeletal muscle.
Formal Description
Interaction-ID: 15669

drug/chemical compound

NO

increases_activity of

process

glucose import

in skeletal muscle
Comment ARBs, conversely, are able to attenuate the negative effects of AT II on cellular insulin signaling by specifically inhibiting the AT II type 1 receptors. The ARB-related improvement in insulin-stimulated glucose uptake has been documented not only in muscle and hepatic cells, but in adipose tissue as well.
Formal Description
Interaction-ID: 15683

drug/chemical compound

Angiotensin II type 1 receptor blocker

increases_activity of

process

glucose import

in muscle, in liver, in adipose tissue; if insulin-stimulated